In vitro antimicrobial activity of ethanolic fractions of Cryptolepis sanguinolenta
Following claims that some plants have antimicrobial activities against infectious microbes, the in vitro antimicrobial activities of different solvent fractions of ethanolic extract of Cryptolepis sanguinolenta were evaluated against eight standard bacteria and clinical isolates. The solvent partit...
Saved in:
| Published in | Annals of clinical microbiology and antimicrobials Vol. 11; no. 1; p. 16 |
|---|---|
| Main Authors | , , , , |
| Format | Journal Article |
| Language | English |
| Published |
England
BioMed Central Ltd
18.06.2012
BioMed Central BMC |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Following claims that some plants have antimicrobial activities against infectious microbes, the in vitro antimicrobial activities of different solvent fractions of ethanolic extract of Cryptolepis sanguinolenta were evaluated against eight standard bacteria and clinical isolates.
The solvent partitioning protocol involving ethanol, petroleum ether, chloroform, ethyl acetate and water, was used to extract various fractions of dried pulverized Cryptolepis sanguinolenta roots. Qualitative phyto-constituents screening was performed on the ethanol extract, chloroform fraction and the water fraction. The Kirby Bauer disk diffusion method was employed to ascertain the antibiogram of the test organisms while the agar diffusion method was used to investigate the antimicrobial properties of the crude plant extracts. The microplate dilution method aided in finding the MICs while the MBCs were obtained by the method of Nester and friends. The SPSS 16.0 version was used to analyze the percentages of inhibitions and bactericidal activities.
The phytochemical screening revealed the presence of alkaloids, reducing sugars, polyuronides, anthocyanosides and triterpenes. The ethanol extract inhibited 5 out of 8 (62.5%) of the standard organisms and 6 out of 8 (75%) clinical isolates. The petroleum ether fraction inhibited 4 out of 8 (50%) of the standard microbes and 1 out of 8 (12.5%) clinical isolates. It was also observed that the chloroform fraction inhibited the growth of all the organisms (100%). Average inhibition zones of 14.0 ± 1.0 mm to 24.67 ± 0.58 mm was seen in the ethyl acetate fraction which halted the growth of 3 (37.5%) of the standard organisms. Inhibition of 7 (87.5%) of standard strains and 6 (75%) of clinical isolates were observed in the water fraction. The chloroform fraction exhibited bactericidal activity against all the test organisms while the remaining fractions showed varying degrees of bacteriostatic activity.
The study confirmed that fractions of Cryptolepis sanguinolenta have antimicrobial activity. The chloroform fraction had the highest activity, followed by water, ethanol, petroleum ether and ethyl acetate respectively. Only the chloroform fraction exhibited bactericidal activity and further investigations are needed to ascertain its safety and prospects of drug development. |
|---|---|
| AbstractList | Background Following claims that some plants have antimicrobial activities against infectious microbes, the in vitro antimicrobial activities of different solvent fractions of ethanolic extract of Cryptolepis sanguinolenta were evaluated against eight standard bacteria and clinical isolates. Methods The solvent partitioning protocol involving ethanol, petroleum ether, chloroform, ethyl acetate and water, was used to extract various fractions of dried pulverized Cryptolepis sanguinolenta roots. Qualitative phyto-constituents screening was performed on the ethanol extract, chloroform fraction and the water fraction. The Kirby Bauer disk diffusion method was employed to ascertain the antibiogram of the test organisms while the agar diffusion method was used to investigate the antimicrobial properties of the crude plant extracts. The microplate dilution method aided in finding the MICs while the MBCs were obtained by the method of Nester and friends. The SPSS 16.0 version was used to analyze the percentages of inhibitions and bactericidal activities. Results The phytochemical screening revealed the presence of alkaloids, reducing sugars, polyuronides, anthocyanosides and triterpenes. The ethanol extract inhibited 5 out of 8 (62.5%) of the standard organisms and 6 out of 8 (75%) clinical isolates. The petroleum ether fraction inhibited 4 out of 8 (50%) of the standard microbes and 1 out of 8 (12.5%) clinical isolates. It was also observed that the chloroform fraction inhibited the growth of all the organisms (100%). Average inhibition zones of 14.0 [+ or -] 1.0 mm to 24.67 [+ or -] 0.58 mm was seen in the ethyl acetate fraction which halted the growth of 3 (37.5%) of the standard organisms. Inhibition of 7 (87.5%) of standard strains and 6 (75%) of clinical isolates were observed in the water fraction. The chloroform fraction exhibited bactericidal activity against all the test organisms while the remaining fractions showed varying degrees of bacteriostatic activity. Conclusion The study confirmed that fractions of Cryptolepis sanguinolenta have antimicrobial activity. The chloroform fraction had the highest activity, followed by water, ethanol, petroleum ether and ethyl acetate respectively. Only the chloroform fraction exhibited bactericidal activity and further investigations are needed to ascertain its safety and prospects of drug development. BACKGROUND: Following claims that some plants have antimicrobial activities against infectious microbes, the in vitro antimicrobial activities of different solvent fractions of ethanolic extract of Cryptolepis sanguinolenta were evaluated against eight standard bacteria and clinical isolates. METHODS: The solvent partitioning protocol involving ethanol, petroleum ether, chloroform, ethyl acetate and water, was used to extract various fractions of dried pulverized Cryptolepis sanguinolenta roots. Qualitative phyto-constituents screening was performed on the ethanol extract, chloroform fraction and the water fraction. The Kirby Bauer disk diffusion method was employed to ascertain the antibiogram of the test organisms while the agar diffusion method was used to investigate the antimicrobial properties of the crude plant extracts. The microplate dilution method aided in finding the MICs while the MBCs were obtained by the method of Nester and friends. The SPSS 16.0 version was used to analyze the percentages of inhibitions and bactericidal activities. RESULTS: The phytochemical screening revealed the presence of alkaloids, reducing sugars, polyuronides, anthocyanosides and triterpenes. The ethanol extract inhibited 5 out of 8 (62.5%) of the standard organisms and 6 out of 8 (75%) clinical isolates. The petroleum ether fraction inhibited 4 out of 8 (50%) of the standard microbes and 1 out of 8 (12.5%) clinical isolates. It was also observed that the chloroform fraction inhibited the growth of all the organisms (100%). Average inhibition zones of 14.0 ± 1.0 mm to 24.67 ± 0.58 mm was seen in the ethyl acetate fraction which halted the growth of 3 (37.5%) of the standard organisms. Inhibition of 7 (87.5%) of standard strains and 6 (75%) of clinical isolates were observed in the water fraction. The chloroform fraction exhibited bactericidal activity against all the test organisms while the remaining fractions showed varying degrees of bacteriostatic activity. CONCLUSION: The study confirmed that fractions of Cryptolepis sanguinolenta have antimicrobial activity. The chloroform fraction had the highest activity, followed by water, ethanol, petroleum ether and ethyl acetate respectively. Only the chloroform fraction exhibited bactericidal activity and further investigations are needed to ascertain its safety and prospects of drug development. Doc number: 16 Abstract Background: Following claims that some plants have antimicrobial activities against infectious microbes, the in vitro antimicrobial activities of different solvent fractions of ethanolic extract of Cryptolepis sanguinolenta were evaluated against eight standard bacteria and clinical isolates. Methods: The solvent partitioning protocol involving ethanol, petroleum ether, chloroform, ethyl acetate and water, was used to extract various fractions of dried pulverized Cryptolepis sanguinolenta roots. Qualitative phyto-constituents screening was performed on the ethanol extract, chloroform fraction and the water fraction. The Kirby Bauer disk diffusion method was employed to ascertain the antibiogram of the test organisms while the agar diffusion method was used to investigate the antimicrobial properties of the crude plant extracts. The microplate dilution method aided in finding the MICs while the MBCs were obtained by the method of Nester and friends. The SPSS 16.0 version was used to analyze the percentages of inhibitions and bactericidal activities. Results: The phytochemical screening revealed the presence of alkaloids, reducing sugars, polyuronides, anthocyanosides and triterpenes. The ethanol extract inhibited 5 out of 8 (62.5%) of the standard organisms and 6 out of 8 (75%) clinical isolates. The petroleum ether fraction inhibited 4 out of 8 (50%) of the standard microbes and 1 out of 8 (12.5%) clinical isolates. It was also observed that the chloroform fraction inhibited the growth of all the organisms (100%). Average inhibition zones of 14.0 ± 1.0 mm to 24.67 ± 0.58 mm was seen in the ethyl acetate fraction which halted the growth of 3 (37.5%) of the standard organisms. Inhibition of 7 (87.5%) of standard strains and 6 (75%) of clinical isolates were observed in the water fraction. The chloroform fraction exhibited bactericidal activity against all the test organisms while the remaining fractions showed varying degrees of bacteriostatic activity. Conclusion: The study confirmed that fractions of Cryptolepis sanguinolenta have antimicrobial activity. The chloroform fraction had the highest activity, followed by water, ethanol, petroleum ether and ethyl acetate respectively. Only the chloroform fraction exhibited bactericidal activity and further investigations are needed to ascertain its safety and prospects of drug development. Background: Following claims that some plants have antimicrobial activities against infectious microbes, the in vitro antimicrobial activities of different solvent fractions of ethanolic extract of Cryptolepis sanguinolenta were evaluated against eight standard bacteria and clinical isolates. Methods: The solvent partitioning protocol involving ethanol, petroleum ether, chloroform, ethyl acetate and water, was used to extract various fractions of dried pulverized Cryptolepis sanguinolenta roots. Qualitative phyto-constituents screening was performed on the ethanol extract, chloroform fraction and the water fraction. The Kirby Bauer disk diffusion method was employed to ascertain the antibiogram of the test organisms while the agar diffusion method was used to investigate the antimicrobial properties of the crude plant extracts. The microplate dilution method aided in finding the MICs while the MBCs were obtained by the method of Nester and friends. The SPSS 16.0 version was used to analyze the percentages of inhibitions and bactericidal activities. Results: The phytochemical screening revealed the presence of alkaloids, reducing sugars, polyuronides, anthocyanosides and triterpenes. The ethanol extract inhibited 5 out of 8 (62.5%) of the standard organisms and 6 out of 8 (75%) clinical isolates. The petroleum ether fraction inhibited 4 out of 8 (50%) of the standard microbes and 1 out of 8 (12.5%) clinical isolates. It was also observed that the chloroform fraction inhibited the growth of all the organisms (100%). Average inhibition zones of 14.0 plus or minus 1.0 mm to 24.67 plus or minus 0.58 mm was seen in the ethyl acetate fraction which halted the growth of 3 (37.5%) of the standard organisms. Inhibition of 7 (87.5%) of standard strains and 6 (75%) of clinical isolates were observed in the water fraction. The chloroform fraction exhibited bactericidal activity against all the test organisms while the remaining fractions showed varying degrees of bacteriostatic activity. Conclusion: The study confirmed that fractions of Cryptolepis sanguinolenta have antimicrobial activity. The chloroform fraction had the highest activity, followed by water, ethanol, petroleum ether and ethyl acetate respectively. Only the chloroform fraction exhibited bactericidal activity and further investigations are needed to ascertain its safety and prospects of drug development. Following claims that some plants have antimicrobial activities against infectious microbes, the in vitro antimicrobial activities of different solvent fractions of ethanolic extract of Cryptolepis sanguinolenta were evaluated against eight standard bacteria and clinical isolates. The solvent partitioning protocol involving ethanol, petroleum ether, chloroform, ethyl acetate and water, was used to extract various fractions of dried pulverized Cryptolepis sanguinolenta roots. Qualitative phyto-constituents screening was performed on the ethanol extract, chloroform fraction and the water fraction. The Kirby Bauer disk diffusion method was employed to ascertain the antibiogram of the test organisms while the agar diffusion method was used to investigate the antimicrobial properties of the crude plant extracts. The microplate dilution method aided in finding the MICs while the MBCs were obtained by the method of Nester and friends. The SPSS 16.0 version was used to analyze the percentages of inhibitions and bactericidal activities. The phytochemical screening revealed the presence of alkaloids, reducing sugars, polyuronides, anthocyanosides and triterpenes. The ethanol extract inhibited 5 out of 8 (62.5%) of the standard organisms and 6 out of 8 (75%) clinical isolates. The petroleum ether fraction inhibited 4 out of 8 (50%) of the standard microbes and 1 out of 8 (12.5%) clinical isolates. It was also observed that the chloroform fraction inhibited the growth of all the organisms (100%). Average inhibition zones of 14.0 ± 1.0 mm to 24.67 ± 0.58 mm was seen in the ethyl acetate fraction which halted the growth of 3 (37.5%) of the standard organisms. Inhibition of 7 (87.5%) of standard strains and 6 (75%) of clinical isolates were observed in the water fraction. The chloroform fraction exhibited bactericidal activity against all the test organisms while the remaining fractions showed varying degrees of bacteriostatic activity. The study confirmed that fractions of Cryptolepis sanguinolenta have antimicrobial activity. The chloroform fraction had the highest activity, followed by water, ethanol, petroleum ether and ethyl acetate respectively. Only the chloroform fraction exhibited bactericidal activity and further investigations are needed to ascertain its safety and prospects of drug development. Abstract Background Following claims that some plants have antimicrobial activities against infectious microbes, the in vitro antimicrobial activities of different solvent fractions of ethanolic extract of Cryptolepis sanguinolenta were evaluated against eight standard bacteria and clinical isolates. Methods The solvent partitioning protocol involving ethanol, petroleum ether, chloroform, ethyl acetate and water, was used to extract various fractions of dried pulverized Cryptolepis sanguinolenta roots. Qualitative phyto-constituents screening was performed on the ethanol extract, chloroform fraction and the water fraction. The Kirby Bauer disk diffusion method was employed to ascertain the antibiogram of the test organisms while the agar diffusion method was used to investigate the antimicrobial properties of the crude plant extracts. The microplate dilution method aided in finding the MICs while the MBCs were obtained by the method of Nester and friends. The SPSS 16.0 version was used to analyze the percentages of inhibitions and bactericidal activities. Results The phytochemical screening revealed the presence of alkaloids, reducing sugars, polyuronides, anthocyanosides and triterpenes. The ethanol extract inhibited 5 out of 8 (62.5%) of the standard organisms and 6 out of 8 (75%) clinical isolates. The petroleum ether fraction inhibited 4 out of 8 (50%) of the standard microbes and 1 out of 8 (12.5%) clinical isolates. It was also observed that the chloroform fraction inhibited the growth of all the organisms (100%). Average inhibition zones of 14.0 ± 1.0 mm to 24.67 ± 0.58 mm was seen in the ethyl acetate fraction which halted the growth of 3 (37.5%) of the standard organisms. Inhibition of 7 (87.5%) of standard strains and 6 (75%) of clinical isolates were observed in the water fraction. The chloroform fraction exhibited bactericidal activity against all the test organisms while the remaining fractions showed varying degrees of bacteriostatic activity. Conclusion The study confirmed that fractions of Cryptolepis sanguinolenta have antimicrobial activity. The chloroform fraction had the highest activity, followed by water, ethanol, petroleum ether and ethyl acetate respectively. Only the chloroform fraction exhibited bactericidal activity and further investigations are needed to ascertain its safety and prospects of drug development. Following claims that some plants have antimicrobial activities against infectious microbes, the in vitro antimicrobial activities of different solvent fractions of ethanolic extract of Cryptolepis sanguinolenta were evaluated against eight standard bacteria and clinical isolates. The solvent partitioning protocol involving ethanol, petroleum ether, chloroform, ethyl acetate and water, was used to extract various fractions of dried pulverized Cryptolepis sanguinolenta roots. Qualitative phyto-constituents screening was performed on the ethanol extract, chloroform fraction and the water fraction. The Kirby Bauer disk diffusion method was employed to ascertain the antibiogram of the test organisms while the agar diffusion method was used to investigate the antimicrobial properties of the crude plant extracts. The microplate dilution method aided in finding the MICs while the MBCs were obtained by the method of Nester and friends. The SPSS 16.0 version was used to analyze the percentages of inhibitions and bactericidal activities. The phytochemical screening revealed the presence of alkaloids, reducing sugars, polyuronides, anthocyanosides and triterpenes. The ethanol extract inhibited 5 out of 8 (62.5%) of the standard organisms and 6 out of 8 (75%) clinical isolates. The petroleum ether fraction inhibited 4 out of 8 (50%) of the standard microbes and 1 out of 8 (12.5%) clinical isolates. It was also observed that the chloroform fraction inhibited the growth of all the organisms (100%). Average inhibition zones of 14.0 [+ or -] 1.0 mm to 24.67 [+ or -] 0.58 mm was seen in the ethyl acetate fraction which halted the growth of 3 (37.5%) of the standard organisms. Inhibition of 7 (87.5%) of standard strains and 6 (75%) of clinical isolates were observed in the water fraction. The chloroform fraction exhibited bactericidal activity against all the test organisms while the remaining fractions showed varying degrees of bacteriostatic activity. The study confirmed that fractions of Cryptolepis sanguinolenta have antimicrobial activity. The chloroform fraction had the highest activity, followed by water, ethanol, petroleum ether and ethyl acetate respectively. Only the chloroform fraction exhibited bactericidal activity and further investigations are needed to ascertain its safety and prospects of drug development. Abstract Background Following claims that some plants have antimicrobial activities against infectious microbes, the in vitro antimicrobial activities of different solvent fractions of ethanolic extract of Cryptolepis sanguinolenta were evaluated against eight standard bacteria and clinical isolates. Methods The solvent partitioning protocol involving ethanol, petroleum ether, chloroform, ethyl acetate and water, was used to extract various fractions of dried pulverized Cryptolepis sanguinolenta roots. Qualitative phyto-constituents screening was performed on the ethanol extract, chloroform fraction and the water fraction. The Kirby Bauer disk diffusion method was employed to ascertain the antibiogram of the test organisms while the agar diffusion method was used to investigate the antimicrobial properties of the crude plant extracts. The microplate dilution method aided in finding the MICs while the MBCs were obtained by the method of Nester and friends. The SPSS 16.0 version was used to analyze the percentages of inhibitions and bactericidal activities. Results The phytochemical screening revealed the presence of alkaloids, reducing sugars, polyuronides, anthocyanosides and triterpenes. The ethanol extract inhibited 5 out of 8 (62.5%) of the standard organisms and 6 out of 8 (75%) clinical isolates. The petroleum ether fraction inhibited 4 out of 8 (50%) of the standard microbes and 1 out of 8 (12.5%) clinical isolates. It was also observed that the chloroform fraction inhibited the growth of all the organisms (100%). Average inhibition zones of 14.0 ± 1.0 mm to 24.67 ± 0.58 mm was seen in the ethyl acetate fraction which halted the growth of 3 (37.5%) of the standard organisms. Inhibition of 7 (87.5%) of standard strains and 6 (75%) of clinical isolates were observed in the water fraction. The chloroform fraction exhibited bactericidal activity against all the test organisms while the remaining fractions showed varying degrees of bacteriostatic activity. Conclusion The study confirmed that fractions of Cryptolepis sanguinolenta have antimicrobial activity. The chloroform fraction had the highest activity, followed by water, ethanol, petroleum ether and ethyl acetate respectively. Only the chloroform fraction exhibited bactericidal activity and further investigations are needed to ascertain its safety and prospects of drug development. BACKGROUNDFollowing claims that some plants have antimicrobial activities against infectious microbes, the in vitro antimicrobial activities of different solvent fractions of ethanolic extract of Cryptolepis sanguinolenta were evaluated against eight standard bacteria and clinical isolates. METHODSThe solvent partitioning protocol involving ethanol, petroleum ether, chloroform, ethyl acetate and water, was used to extract various fractions of dried pulverized Cryptolepis sanguinolenta roots. Qualitative phyto-constituents screening was performed on the ethanol extract, chloroform fraction and the water fraction. The Kirby Bauer disk diffusion method was employed to ascertain the antibiogram of the test organisms while the agar diffusion method was used to investigate the antimicrobial properties of the crude plant extracts. The microplate dilution method aided in finding the MICs while the MBCs were obtained by the method of Nester and friends. The SPSS 16.0 version was used to analyze the percentages of inhibitions and bactericidal activities. RESULTSThe phytochemical screening revealed the presence of alkaloids, reducing sugars, polyuronides, anthocyanosides and triterpenes. The ethanol extract inhibited 5 out of 8 (62.5%) of the standard organisms and 6 out of 8 (75%) clinical isolates. The petroleum ether fraction inhibited 4 out of 8 (50%) of the standard microbes and 1 out of 8 (12.5%) clinical isolates. It was also observed that the chloroform fraction inhibited the growth of all the organisms (100%). Average inhibition zones of 14.0 ± 1.0 mm to 24.67 ± 0.58 mm was seen in the ethyl acetate fraction which halted the growth of 3 (37.5%) of the standard organisms. Inhibition of 7 (87.5%) of standard strains and 6 (75%) of clinical isolates were observed in the water fraction. The chloroform fraction exhibited bactericidal activity against all the test organisms while the remaining fractions showed varying degrees of bacteriostatic activity. CONCLUSIONThe study confirmed that fractions of Cryptolepis sanguinolenta have antimicrobial activity. The chloroform fraction had the highest activity, followed by water, ethanol, petroleum ether and ethyl acetate respectively. Only the chloroform fraction exhibited bactericidal activity and further investigations are needed to ascertain its safety and prospects of drug development. |
| ArticleNumber | 16 |
| Audience | Academic |
| Author | Mills-Robertson, Felix C Tay, Samuel C K Duker-Eshun, Goerge Walana, Williams Badu, Kingsley |
| AuthorAffiliation | 2 Department of Clinical Microbiology, School of Medical Sciences, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana 3 Kenya Medical Research Institute Center for Global Health, Research Climate and Human Health Research Unit, Kisumu, Kenya 1 Department of Microbiology, Centre for Scientific Research into Plant Medicine, Mampong-Akwapim, Ghana |
| AuthorAffiliation_xml | – name: 1 Department of Microbiology, Centre for Scientific Research into Plant Medicine, Mampong-Akwapim, Ghana – name: 3 Kenya Medical Research Institute Center for Global Health, Research Climate and Human Health Research Unit, Kisumu, Kenya – name: 2 Department of Clinical Microbiology, School of Medical Sciences, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana |
| Author_xml | – sequence: 1 givenname: Felix C surname: Mills-Robertson fullname: Mills-Robertson, Felix C organization: Department of Microbiology, Centre for Scientific Research into Plant Medicine, Mampong-Akwapim, Ghana – sequence: 2 givenname: Samuel C K surname: Tay fullname: Tay, Samuel C K – sequence: 3 givenname: Goerge surname: Duker-Eshun fullname: Duker-Eshun, Goerge – sequence: 4 givenname: Williams surname: Walana fullname: Walana, Williams – sequence: 5 givenname: Kingsley surname: Badu fullname: Badu, Kingsley |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/22709723$$D View this record in MEDLINE/PubMed |
| BookMark | eNqFkktr3DAUhUVJaR7turti6KYbJ3pZljaFZOhjINBF27W4lqWJBo80lezA_PvKnXSaKSlFApmjo4_re885OgkxWIReE3xJiBRXhLeixi0h9bzFM3R2UE4efZ-i85zXGFOMRfsCnVLaYtVSdoa-LkN178cUKwij33iTYudhqMCMvui7KrrKjncQ4uBN5dKsx5BneZF22zEOdutzlSGsJl9MNozwEj13MGT76uG8QN8_fvi2-Fzffvm0XFzf1p3gYqxFRzHnEjpmsBPYuJ5Dr2hHJFfCMUbbUmUPTEArJBa0F6JrpFVUuoYapdgFWu65fYS13ia_gbTTEbz-JcS00pBGbwarOW9A9i2wRhkOspHUUI6VEE442lFWWO_3rO3UbWxvyn8kGI6gxzfB3-lVvNeMt4yqpgBu9oDOx38Ajm9M3Oh5QHoekJ63KJB3D1Wk-GOyedQbn40dBgg2TlkTRmVDGMHy_1ZSzEQSRYr17V_WdZxSKKOZXZRyIhX_41pBaZgPLpYyzQzV1w3jlEtB5j5dPuEqq7clPCWczhf96MHV_kFJVs7JukNLCNZzhp9owpvHozj4f4eW_QRbxOuu |
| CitedBy_id | crossref_primary_10_1186_s12906_023_04006_8 crossref_primary_10_1007_s40242_017_6502_6 crossref_primary_10_3389_fcimb_2021_624745 crossref_primary_10_13103_JFHS_2014_29_1_060 crossref_primary_10_1155_2017_3026370 crossref_primary_10_3389_fphar_2021_615147 crossref_primary_10_5897_JMPR2018_6667 crossref_primary_10_5812_amh_80148 crossref_primary_10_1080_87559129_2021_1944183 crossref_primary_10_6000_1927_5129_2016_12_17 crossref_primary_10_1016_j_eujim_2019_101011 crossref_primary_10_13103_JFHS_2013_28_3_234 crossref_primary_10_1155_2014_761613 crossref_primary_10_3389_fmed_2020_00006 crossref_primary_10_1097_IM9_0000000000000069 crossref_primary_10_2139_ssrn_3955297 crossref_primary_10_48198_NJPAS_20_B15 crossref_primary_10_1016_j_sajb_2020_06_030 crossref_primary_10_1002_cbdv_202000526 crossref_primary_10_13103_JFHS_2013_28_4_349 crossref_primary_10_1002_cbdv_202000666 crossref_primary_10_3390_microorganisms11071759 crossref_primary_10_1016_j_ejmech_2014_03_060 |
| Cites_doi | 10.1590/S0074-02762006000300011 10.1186/1472-6882-5-6 10.1016/0378-8741(94)90071-X 10.1002/ptr.2999 10.1111/j.1365-2672.1991.tb02963.x 10.1021/jo00174a010 10.1016/S0305-1978(02)00075-3 10.1155/2010/464087 10.1016/0378-8741(96)01429-8 10.1111/j.1472-765X.2004.01625.x 10.3201/eid0501.990103 10.1021/jm9704816 10.1513/pats.200504-037SR 10.1055/s-2006-957563 10.1055/s-2006-961760 10.1016/S1286-4579(01)01375-2 |
| ContentType | Journal Article |
| Copyright | COPYRIGHT 2012 BioMed Central Ltd. 2012 Mills-Robertson et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Copyright ©2012 Mills-Robertson et al.; licensee BioMed Central Ltd. 2012 Mills-Robertson et al.; licensee BioMed Central Ltd. |
| Copyright_xml | – notice: COPYRIGHT 2012 BioMed Central Ltd. – notice: 2012 Mills-Robertson et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. – notice: Copyright ©2012 Mills-Robertson et al.; licensee BioMed Central Ltd. 2012 Mills-Robertson et al.; licensee BioMed Central Ltd. |
| DBID | CGR CUY CVF ECM EIF NPM AAYXX CITATION 3V. 7QL 7T7 7U7 7U9 7X7 7XB 88E 8C1 8FD 8FE 8FH 8FI 8FJ 8FK 8G5 ABUWG AFKRA AZQEC BBNVY BENPR BHPHI C1K CCPQU DWQXO FR3 FYUFA GHDGH GNUQQ GUQSH H94 HCIFZ K9. LK8 M0S M1P M2O M7N M7P MBDVC P64 PIMPY PQEST PQQKQ PQUKI PRINS Q9U 7X8 5PM DOA |
| DOI | 10.1186/1476-0711-11-16 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef ProQuest Central (Corporate) Bacteriology Abstracts (Microbiology B) Industrial and Applied Microbiology Abstracts (Microbiology A) Toxicology Abstracts Virology and AIDS Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Public Health Database Technology Research Database ProQuest SciTech Collection ProQuest Natural Science Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) Research Library (Alumni Edition) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials Biological Science Collection ProQuest Central Natural Science Collection Environmental Sciences and Pollution Management ProQuest One Community College ProQuest Central Korea Engineering Research Database Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student Research Library Prep AIDS and Cancer Research Abstracts SciTech Premium Collection ProQuest Health & Medical Complete (Alumni) ProQuest Biological Science Collection Health & Medical Collection (Alumni Edition) Medical Database Research Library Algology Mycology and Protozoology Abstracts (Microbiology C) Biological Science Database Research Library (Corporate) Biotechnology and BioEngineering Abstracts Publicly Available Content Database ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China ProQuest Central Basic MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef Publicly Available Content Database Research Library Prep ProQuest Central Student Technology Research Database ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College Research Library (Alumni Edition) ProQuest Natural Science Collection ProQuest Central China Environmental Sciences and Pollution Management ProQuest Central Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Natural Science Collection ProQuest Central Korea Bacteriology Abstracts (Microbiology B) Algology Mycology and Protozoology Abstracts (Microbiology C) Biological Science Collection AIDS and Cancer Research Abstracts ProQuest Research Library Industrial and Applied Microbiology Abstracts (Microbiology A) ProQuest Medical Library (Alumni) ProQuest Public Health Virology and AIDS Abstracts ProQuest Biological Science Collection ProQuest Central Basic Toxicology Abstracts ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database ProQuest SciTech Collection ProQuest Hospital Collection (Alumni) Biotechnology and BioEngineering Abstracts ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition Engineering Research Database ProQuest One Academic ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | Publicly Available Content Database Engineering Research Database MEDLINE CrossRef MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 4 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Biology |
| EISSN | 1476-0711 |
| EndPage | 16 |
| ExternalDocumentID | oai_doaj_org_article_445a8d7a359c4a8582c240966f6f2b23 oai_biomedcentral_com_1476_0711_11_16 2789721001 A534248613 10_1186_1476_0711_11_16 22709723 |
| Genre | Research Support, Non-U.S. Gov't Journal Article |
| GeographicLocations | Ghana |
| GeographicLocations_xml | – name: Ghana |
| GroupedDBID | --- -A0 0R~ 23M 2VQ 2WC 3V. 4.4 53G 5GY 5VS 6J9 7X7 88E 8C1 8CJ 8FE 8FH 8FI 8FJ 8G5 AAFWJ AAJSJ ABUWG ACGFO ACGFS ACPRK ACRMQ ADBBV ADINQ ADRAZ ADUKV AENEX AFKRA AFPKN AFRAH AHBYD AHMBA AHSBF AHYZX ALIPV ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIJS AZQEC BAPOH BAWUL BBNVY BCNDV BENPR BFQNJ BHPHI BMC BPHCQ BVXVI C24 C6C CCPQU CGR CS3 CUY CVF D1J DIK DWQXO E3Z EBD EBLON EBS ECGQY ECM EIF EJD EMB EMOBN F5P FYUFA GNUQQ GROUPED_DOAJ GUQSH GX1 H13 HCIFZ HMCUK HYE IAO IGS IHR INH INR IPNFZ ITC KQ8 LK8 M1P M2O M48 M7P MM. M~E NPM O5R O5S OK1 P2P PGMZT PIMPY PQQKQ PROAC PSQYO RBZ RIG RNS ROL RPM RSV SBL SOJ SV3 TR2 UKHRP W2D WOQ WOW XSB AAYXX CITATION AFGXO 7QL 7T7 7U7 7U9 7XB 8FD 8FK C1K FR3 H94 K9. M7N MBDVC P64 PQEST PQUKI PRINS Q9U 7X8 ABVAZ AFNRJ 5PM |
| ID | FETCH-LOGICAL-b646t-6b20448ab3c0f60cfd4ad92b18496f3327270da36a768062d66b58e928f52c993 |
| IEDL.DBID | RPM |
| ISSN | 1476-0711 |
| IngestDate | Fri Oct 04 13:10:32 EDT 2024 Tue Sep 17 20:58:20 EDT 2024 Wed May 22 07:15:17 EDT 2024 Mon Aug 12 07:03:39 EDT 2024 Fri Aug 16 23:59:57 EDT 2024 Thu Oct 10 19:38:07 EDT 2024 Wed Aug 14 18:51:34 EDT 2024 Tue Aug 13 05:22:45 EDT 2024 Thu Sep 12 19:30:14 EDT 2024 Sat Sep 28 07:55:42 EDT 2024 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Language | English |
| License | This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-b646t-6b20448ab3c0f60cfd4ad92b18496f3327270da36a768062d66b58e928f52c993 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 ObjectType-Article-2 ObjectType-Feature-1 |
| OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3473295/ |
| PMID | 22709723 |
| PQID | 1112241894 |
| PQPubID | 44056 |
| PageCount | 1 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_445a8d7a359c4a8582c240966f6f2b23 pubmedcentral_primary_oai_pubmedcentral_nih_gov_3473295 biomedcentral_primary_oai_biomedcentral_com_1476_0711_11_16 proquest_miscellaneous_1328513108 proquest_miscellaneous_1113218191 proquest_journals_1112241894 gale_infotracmisc_A534248613 gale_infotracacademiconefile_A534248613 crossref_primary_10_1186_1476_0711_11_16 pubmed_primary_22709723 |
| PublicationCentury | 2000 |
| PublicationDate | 2012-06-18 |
| PublicationDateYYYYMMDD | 2012-06-18 |
| PublicationDate_xml | – month: 06 year: 2012 text: 2012-06-18 day: 18 |
| PublicationDecade | 2010 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England – name: London |
| PublicationTitle | Annals of clinical microbiology and antimicrobials |
| PublicationTitleAlternate | Ann Clin Microbiol Antimicrob |
| PublicationYear | 2012 |
| Publisher | BioMed Central Ltd BioMed Central BMC |
| Publisher_xml | – name: BioMed Central Ltd – name: BioMed Central – name: BMC |
| References | 11991792 - Altern Med Rev. 2002 Apr;7(2):130-7 9933989 - Planta Med. 1998 Dec;64(8):711-3 16955742 - Indian J Biochem Biophys. 2005 Dec;42(6):395-7 9752592 - Can Vet J. 1998 Sep;39(9):559-65 7853867 - J Ethnopharmacol. 1994 Oct;44(2):73-7 8720383 - Planta Med. 1996 Feb;62(1):22-7 15762997 - BMC Complement Altern Med. 2005;5:6 16267349 - Proc Am Thorac Soc. 2005;2(4):282-9; discussion 290-1 10081668 - Emerg Infect Dis. 1999 Jan-Feb;5(1):18-27 8887021 - J Ethnopharmacol. 1996 Sep;53(3):143-7 16862324 - Mem Inst Oswaldo Cruz. 2006 May;101(3):287-90 20066659 - Phytother Res. 2010 Aug;24(8):1151-7 15022164 - Phytother Res. 2004 Feb;18(2):128-30 21326984 - Ghana Med J. 2010 Mar;44(1):3-9 20162076 - Afr J Tradit Complement Altern Med. 2006 Aug 28;4(1):87-93 15612998 - Lett Appl Microbiol. 2005;40(1):24-9 11358718 - Microbes Infect. 2001 Mar;3(3):237-47 9526563 - J Med Chem. 1998 Mar 12;41(6):894-901 A Paulo (259_CR16) 1994; 44 MM Iwu (259_CR1) 1993 E Jawetz (259_CR22) 1996 V Navarro (259_CR37) 1996; 53 WHO (259_CR34) 2000 LG Boye (259_CR4) 1990; 4 BS Nayak (259_CR24) 2010; 24 SH Grode (259_CR8) 1983; 48 DA Dhalel (259_CR26) 2011; 2 M Addy (259_CR2) 2003; 60 M Spinella (259_CR32) 2002; 7 National Committee for Clinical Laboratory Standards (NCCLS) (259_CR11) 2000 R Abdel-Massih (259_CR36) 2010; 464087 AB Ojekale (259_CR30) 2007; 25 KA Bugyei (259_CR15) 2010; 44 W Rabsch (259_CR21) 2001; 3 IA Suffredini (259_CR38) 2006; 101 AK Ako-Nai (259_CR19) 2005; 4 DE Bierer (259_CR5) 1998; 41 G Duker-Eshun (259_CR9) 2004; 18 A Sofowora (259_CR10) 1993 National Committee for Clinical Laboratory Standards (259_CR7) 1998 R Slack (259_CR28) 2007 FC Mills-Robertson (259_CR6) 2009; 3 M Ekpo (259_CR31) 2011; 1 KO Akinyemi (259_CR35) 2005; 5 EW Nester (259_CR14) 2004 K Cimanga (259_CR17) 1996; 62 CSN Poppe (259_CR20) 1998; 39 National Center for Infectious Disease, Center for Disease Control and prevention, WHO (259_CR12) 1999 ML Toews (259_CR33) 2005; 2 LBK Mabeku (259_CR25) 2007; 4 IN Okeke (259_CR18) 1999; 5 M Scortichini (259_CR23) 1991; 71 C Akgul (259_CR27) 2005; 42 A Paulo (259_CR3) 2003; 31 JN Eloff (259_CR13) 1998; 64 IK Sawer (259_CR29) 2005; 40 |
| References_xml | – volume: 101 start-page: 287 year: 2006 ident: 259_CR38 publication-title: Mem Inst Oswaldo Cruz doi: 10.1590/S0074-02762006000300011 contributor: fullname: IA Suffredini – volume: 5 start-page: 6 year: 2005 ident: 259_CR35 publication-title: BMC Compl Alternative Med doi: 10.1186/1472-6882-5-6 contributor: fullname: KO Akinyemi – volume: 4 start-page: 32 year: 1990 ident: 259_CR4 publication-title: Plants Traditional Med contributor: fullname: LG Boye – volume: 44 start-page: 73 issue: 2 year: 1994 ident: 259_CR16 publication-title: J Ethnopharmacol doi: 10.1016/0378-8741(94)90071-X contributor: fullname: A Paulo – volume: 4 start-page: 87 issue: 1 year: 2007 ident: 259_CR25 publication-title: Afr J Tradit Compl Alternative Med contributor: fullname: LBK Mabeku – start-page: 221 volume-title: The Handbook of African Medicinal Plants year: 1993 ident: 259_CR1 contributor: fullname: MM Iwu – volume: 2 start-page: 04 issue: 3 year: 2011 ident: 259_CR26 publication-title: J Exp Sci contributor: fullname: DA Dhalel – start-page: 224 volume-title: Medicinal plants and traditional medicine year: 1993 ident: 259_CR10 contributor: fullname: A Sofowora – volume: 4 start-page: 816 issue: 8 year: 2005 ident: 259_CR19 publication-title: Afr J Biotechnol contributor: fullname: AK Ako-Nai – volume-title: Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved Standard M7-A4 year: 2000 ident: 259_CR11 contributor: fullname: National Committee for Clinical Laboratory Standards (NCCLS) – start-page: 71 volume-title: Laboratory Methods for the Diagnosis of Epidemic Dysentery and Cholera, Center for Disease Control and prevention year: 1999 ident: 259_CR12 contributor: fullname: National Center for Infectious Disease, Center for Disease Control and prevention, WHO – volume: 24 start-page: 1151 issue: 8 year: 2010 ident: 259_CR24 publication-title: Phytother Res doi: 10.1002/ptr.2999 contributor: fullname: BS Nayak – volume: 39 start-page: 559 year: 1998 ident: 259_CR20 publication-title: Can Vet J contributor: fullname: CSN Poppe – volume: 71 start-page: 109 year: 1991 ident: 259_CR23 publication-title: J Bacteriol doi: 10.1111/j.1365-2672.1991.tb02963.x contributor: fullname: M Scortichini – volume: 48 start-page: 5203 year: 1983 ident: 259_CR8 publication-title: J Org Chem doi: 10.1021/jo00174a010 contributor: fullname: SH Grode – volume: 31 start-page: 155 year: 2003 ident: 259_CR3 publication-title: Biochem Syst Ecol doi: 10.1016/S0305-1978(02)00075-3 contributor: fullname: A Paulo – volume-title: Performance standards for antimicrobial disk susceptibility tests. Approved standard M2-A6 year: 1998 ident: 259_CR7 contributor: fullname: National Committee for Clinical Laboratory Standards – volume: 464087 start-page: 8 year: 2010 ident: 259_CR36 publication-title: J Bot Vol doi: 10.1155/2010/464087 contributor: fullname: R Abdel-Massih – volume: 53 start-page: 143 year: 1996 ident: 259_CR37 publication-title: J Ethnopharmacol doi: 10.1016/0378-8741(96)01429-8 contributor: fullname: V Navarro – volume: 40 start-page: 24 issue: 1 year: 2005 ident: 259_CR29 publication-title: Lett Appl Microbiol doi: 10.1111/j.1472-765X.2004.01625.x contributor: fullname: IK Sawer – volume: 60 start-page: 54 year: 2003 ident: 259_CR2 publication-title: HerbalGram contributor: fullname: M Addy – volume: 7 start-page: 130 issue: 2 year: 2002 ident: 259_CR32 publication-title: Alternative Med Rev contributor: fullname: M Spinella – volume: 18 start-page: 128 year: 2004 ident: 259_CR9 publication-title: Centre Sci Res Plant Med contributor: fullname: G Duker-Eshun – volume: 44 start-page: 3 issue: 1 year: 2010 ident: 259_CR15 publication-title: Ghana Med J contributor: fullname: KA Bugyei – volume-title: General guidelines for methodologies on research and evaluation of traditional medicine year: 2000 ident: 259_CR34 contributor: fullname: WHO – volume: 3 start-page: 476 issue: 9 year: 2009 ident: 259_CR6 publication-title: Afr J Pharm Pharmacol contributor: fullname: FC Mills-Robertson – volume: 5 start-page: 1 issue: 1 year: 1999 ident: 259_CR18 publication-title: Emerg Infect Dis doi: 10.3201/eid0501.990103 contributor: fullname: IN Okeke – volume: 41 start-page: 894 year: 1998 ident: 259_CR5 publication-title: J Med Chem doi: 10.1021/jm9704816 contributor: fullname: DE Bierer – volume: 2 start-page: 282 issue: 4 year: 2005 ident: 259_CR33 publication-title: Proc Am Thorac Soc doi: 10.1513/pats.200504-037SR contributor: fullname: ML Toews – start-page: 57 volume-title: Microbiology and Immunology year: 1996 ident: 259_CR22 contributor: fullname: E Jawetz – volume: 64 start-page: 711 issue: 8 year: 1998 ident: 259_CR13 publication-title: Planta Med doi: 10.1055/s-2006-957563 contributor: fullname: JN Eloff – volume: 62 start-page: 288 issue: 3 year: 1996 ident: 259_CR17 publication-title: Planta Med doi: 10.1055/s-2006-961760 contributor: fullname: K Cimanga – volume: 42 start-page: 395 year: 2005 ident: 259_CR27 publication-title: Indian J Biochem Biophys contributor: fullname: C Akgul – start-page: 173 volume-title: Medical Microbiology year: 2007 ident: 259_CR28 contributor: fullname: R Slack – volume: 25 start-page: 176 issue: 2 year: 2007 ident: 259_CR30 publication-title: Nigerian Food Journal contributor: fullname: AB Ojekale – volume: 3 start-page: 227 year: 2001 ident: 259_CR21 publication-title: Microb Infect doi: 10.1016/S1286-4579(01)01375-2 contributor: fullname: W Rabsch – volume: 1 start-page: 1 year: 2011 ident: 259_CR31 publication-title: J Pharm Clin Sci contributor: fullname: M Ekpo – start-page: 640 volume-title: Microbiology year: 2004 ident: 259_CR14 contributor: fullname: EW Nester |
| SSID | ssj0020067 |
| Score | 2.0624871 |
| Snippet | Following claims that some plants have antimicrobial activities against infectious microbes, the in vitro antimicrobial activities of different solvent... Abstract Background Following claims that some plants have antimicrobial activities against infectious microbes, the in vitro antimicrobial activities of... Background Following claims that some plants have antimicrobial activities against infectious microbes, the in vitro antimicrobial activities of different... Doc number: 16 Abstract Background: Following claims that some plants have antimicrobial activities against infectious microbes, the in vitro antimicrobial... BACKGROUNDFollowing claims that some plants have antimicrobial activities against infectious microbes, the in vitro antimicrobial activities of different... Background: Following claims that some plants have antimicrobial activities against infectious microbes, the in vitro antimicrobial activities of different... BACKGROUND: Following claims that some plants have antimicrobial activities against infectious microbes, the in vitro antimicrobial activities of different... Abstract Background Following claims that some plants have antimicrobial activities against infectious microbes, the in vitro antimicrobial activities of... |
| SourceID | doaj pubmedcentral biomedcentral proquest gale crossref pubmed |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database |
| StartPage | 16 |
| SubjectTerms | Agar Alkaloids Analysis Anti-Bacterial Agents - chemistry Anti-Bacterial Agents - isolation & purification Anti-Bacterial Agents - pharmacology Antimicrobial activity Antimicrobial agents Apocynaceae Bacteria Bacteria - drug effects Bacteria - genetics Bacteria - isolation & purification Bacterial Infections - microbiology Bactericidal activity Biological products Chloroform Clinical isolates Cryptolepis - chemistry Diffusion Drug development E coli Esters Ethanol Ethyl acetate Fractions Gram-negative bacteria Humans Materia medica, Vegetable Medical research Microbial Sensitivity Tests Microbiology Minimum inhibitory concentration petroleum ether Physiological aspects Plant extracts Plant Extracts - chemistry Plant Extracts - isolation & purification Plant Extracts - pharmacology Roots Solvents Studies Sugar Teaching hospitals triterpenes |
| SummonAdditionalLinks | – databaseName: BioMedCentral Open Access (Free Resource) dbid: RBZ link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3Ni9UwEB90RfAifltdpYKgl2KbpGmCp93FZRX0oguLl5CPBgtr-3ivK-x_70zbfW52xYvQQ-lMQzuTSX7TZn4BeK2Fl9w2iNyUjQXi_1ho7WLhRbAtIvzKCypO_vxFHh2LTyf1yR-y6Ct_8Csl31WikVRmU1EFWCVvwi1GHOeUmO9_3-ZWNOpOhUSL8sLi85cGrlS2nyYT0sTbf310vjQ9pUsnL81Fh_fg7gIi873Z6_fhRts_gNvztpLnD-Hrxz7_1Y3rIUezdT-7iWsJ9amGgbaKyIeYt_TJnDiB87ieaxs2dPlgfb4ah9N21W3yDX3K7Hr6cT_aR3B8-OHbwVGxbJ5QOCnkWEjHSjS9ddyXUZY-BmGDZg4zOi0j5wyBSxkslxYTjlKyIKWrVauZijXziFoew04_9O1TyFVjlWpj1TRVQPSErsVzF0MQLnBhmwzeJxY1q5kowxB1dSrBKDLkD0P-MHTIDN5e2H9745SZKHlddZ_8k7Q_XcD-YpZIM0LUVoXG8lp7YVWtmEfUglldlJE5xjN4Q941FMD4TN4udQj4rkSFZfZqLphQCHMy2E00MfB8Kr7oH2YJ_A0lVASKlBYZvNqK6U5azNa3w9mkwwlZ6eofOpwhFkbsrTJ4Mne57Wsz9BxtFpdBk3TGxC6ppO9-TNThXDSc6frZf3nsOdxB2MhowVyldmFnXJ-1LxCaje7lFJS_AWULNB0 priority: 500 providerName: BioMedCentral – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1La9wwEBYlUOil9F23aXGh0F5MbEnWg5zS0JAW2ksbyE3oSQ2pvew6hfz7zNjeZUWgvRR8WKSxsWZG0jdezTeEvNfcC2YlIDdlUwX4P1Vau1R5HmwEhN94jsnJ376L8wv-9bK93Cv1hWfCZnrgWXFHnLdWBWlZqz23qlXUwyYEID2JRB2deT6bdhtMLaEWLsJTXpEUmKLTLKQ-jRJHuzbMKMMy51mi-1W2P000_ncX673dKj9Jubc1nT0iDxdMWZ7MY3lM7sX-Cbk_V5m8eUp-fOnLP924HkrQYve7m6iXQB5TGrByRDmkMuIXdKQILtN6TnXYYPPp-mY1Dldx1W3KDX7Z7Hr8H3-0z8jF2eefp-fVUkuhcoKLsRKO1mAJ65ivk6h9CtwGTR0EeFokxijgmDpYJizEH7WgQQjXqqipSi31AGKek4N-6ONLUipplYqpkbIJAKbA0vDbpRC4C4xbWZDjTKNmNfNmGGSyzntgUhm0h0F7GLxEQT5u9b-7cQpUlLgr-gntkz1_agD_MYv_mH_5T0E-oHUNzmd4J2-XtAQYKzJjmZOWccoVoJ6CHGaSMA993r31D7OsAxuMrxAjKc0L8m7XjXfi2bY-DteTDEOgpZu_yDAK0BiguCrIi9nldsOmYDmsHVcQmTljppe8p-9-TUzijEtGdfvqfyjyNXkAYJLiMbpGHZKDcX0d3wBgG93baW7eAqIyOu4 priority: 102 providerName: Directory of Open Access Journals – databaseName: Public Health Database dbid: 8C1 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3da9UwFA86EXwRv61OqSDoS9ltkuYDH2ReHFPQFx3sLeSjcYXZXttO2H_vOW3vdWEw6EPpOSlNTk7yO-n5IOSt5l4wKwG5KRsLwP-x0NrFwvNga0D4pecYnPztuzg-4V9Pq9PlwG1Y3Cq3a-K0UIfO4xn5Aegk7jZK84-bPwVWjcK_q0sJjdvkDlArLN2g1jsXD7SW5ZLOp1TioORSYMBOibFkWOA8CXE_T3amKYH_9WX6yj6V-lBe2ZSOHpD7C5rMD2fxPyS36vYRuTvXl7x8TH58afO_zdh3OYxf87uZki4BPwYzYM2IvIt5jWfnmBw4j_0c5DDg43V_uRm783rTDPmAZ5pNi3_wR_uEnBx9_rk-LpYqCoUTXIyFcHQFMrCO-VUUKx8Dt0FTB6adFpExCghmFSwTFiyPlaBBCFepWlMVK-oBvjwle23X1s9JrqRVqo6llGUAGAUyhnsXQ-AuMG5lRj4kI2o2c8YMgzmsUwqI1qA8DMrD4CUy8n47_ruGk4mixHXWTyif5P3Tg67_ZRaVM5xXVgVpWaU9t6pS1AN8AfMuikgdZRl5h9I1qMnwTd4uAQnQV8yJZQ4rxilXgHcysp9wggb6lLydH2ZZAQbzf75m5M2OjC3Rq62tu4uJhyHE0uUNPIwCKAYQrjLybJ5yu25TkBxWjcuITCZjMi4ppW3OphzijEtGdfXi5k9_Se4BQKToGleqfbI39hf1KwBho3s9ado_-XUxPw priority: 102 providerName: ProQuest – databaseName: Scholars Portal Open Access Journals dbid: M48 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3di9QwEA96IvgiftvzlAqCvlS3SZomiMh5eJzC-aIL9xby0ZyFtd3r9sT9751pu-vFOw76UJJJSeaj-U2bmSHkleJOMFMCcpMmZID_Q6aUDZnj3lSA8HPHMTj5-Js4mvOvJ8XJv3JAEwNXV7p2WE9q3i3e_jlbfwSD_zAYvBTvcl4KDMTJMUYsFzfJLcoZR3U_5ttfCug6l1NunysG_Rfvvoi2qSGb_-V39oVNKz5QeWGHOrxH7k7QMt0fdeE-uVE1D8jtsdjk-iH5_qVJf9d916bAzPpXPWRgAnqMbMACEmkb0go_pGOm4DR0Y8TDCpsPuvWybxfVsl6lK_zAWTf4O783j8j88POPg6NsKqmQWcFFnwlLZyAQY5mbBTFzwXPjFbXg5ykRGKMAZ2beMGHADZkJ6oWwhawUlaGgDrDMY7LTtE31lKSyNFJWIS_L3AOmAoHDvQ3ec-sZN2VC3kcc1csxfYbGhNZxD9iWRnlolIfGSyTkzYb_24GDvyLFZdJPKJ_o-UND253qyf4054WRvjSsUI4bWUjqAMuArxdEoJayhLxG6WpUNJiTM1N0AqwVE2Tp_YJxyiWAn4TsRZRgji7u3uiH3mgzulkIlaTiCXm57caReMStqdrzgYYh3lL5NTSMAkIGRC4T8mRUue2yKUgOS8glpIyUMeJL3NPUP4eE4oyXjKpi9_qpPyN3AC1SPCeXyz2y03fn1XNAZL19MVjaX9A6M9Y priority: 102 providerName: Scholars Portal |
| Title | In vitro antimicrobial activity of ethanolic fractions of Cryptolepis sanguinolenta |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/22709723 https://www.proquest.com/docview/1112241894 https://search.proquest.com/docview/1113218191 https://search.proquest.com/docview/1328513108 http://dx.doi.org/10.1186/1476-0711-11-16 https://pubmed.ncbi.nlm.nih.gov/PMC3473295 https://doaj.org/article/445a8d7a359c4a8582c240966f6f2b23 |
| Volume | 11 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3da9swED_ajsFexr7nrQseDLYXN7EkSzJ7akJLN0gp3QplL0aSrc2Q2CFxB_3vd-fYoV5hDwMjjHQytu5O-p18dwL4kAonuVGI3LTxEeJ_H6Wp9ZETuSkQ4cdOUHDy_FyeXYmv18n1HiR9LEzrtO9seVQtlkdV-av1rVwt3bj3ExtfzGdcKM7SZLwP-4rz3kTvrCyaf7scPrGW41goSVE6MQWQxXRiEWOKctbwv0LcF4OVqU3gf3-avrNODX0o7yxKp0_gcYcmw-PtWz-FvaJ6Bg-350vePodvX6rwd9ms6xDHr1yWbdIlpKdgBjozIqx9WNDeOSUHDv16G-SwoerZ-nbV1ItiVW7CDe1plhX9wW_MC7g6Pfk-O4u6UxQiK4VsImnZBHlgLHcTLyfO58LkKbNo2qXSc84QwUxyw6VBy2MiWS6lTXSRMu0T5hC-vISDqq6K1xBqZbQufKxUnCOMQh7jvfV5LmzOhVEBfB6MaLbaZszIKIf1sAXVKSPWZMSajC4ZwKd-_HcdWxNFy_ukU-LP4PltRb3-mXWSkgmRGJ0rw5PUCaMTzRzCFzTvvPTMMh7AR-JuRpqM7-RMF5CA30o5sbLjhAsmNOKdAA4HlKiBbtjcy0fWzQAbsqwIHelUBPB-10w9yautKuqbloYTxErjf9BwhqAYQbgO4NVW5Haf3UtyAGogjINxGbagSrU5xDsVevPfPd_CI8SOjLzmYn0IB836pniH-KyxI9TKa4WlnsUjeDA9Ob-4HLV7HVjOhcbycvpj1GrtH2x8QLI |
| link.rule.ids | 108,230,315,733,786,790,870,891,2115,2236,12083,12250,21416,24346,24965,27955,27956,31752,31753,33299,33300,33777,33778,43343,43612,43838,53825,53827,76167,76168 |
| linkProvider | National Library of Medicine |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3da9RAEB_0iuhL8bOmVo0g6EvoZXez2eCDtKXlqu0h2kLfls1uVgM1Oe9Sof-9M7nc2aVQyEPITsJm52N_s7szA_C-EFZykyNyU8YniP99UhSlT6xwpkKEn1pBwcmnUzk5F18usothwW0xHKtc2cTeULvW0hr5LuokzTaqEJ9nfxKqGkW7q0MJjfuwQSk31Qg29g-n376vXS4yxkNCn1TJ3VTkkkJ2UoomoxLnQZD7ZTA39Sn8bxvqGzNVeIryxrR09Bg2BzwZ7y0F4Ancq5qn8GBZYfL6Gfw4buK_dTdvYxzB-nfdp11CegpnoKoRcevjilbPKT1w7OfLMIcFPT6YX8-69rKa1Yt4QauadUN7-J15DudHh2cHk2Soo5CUUsgukSUbIxdMye3Yy7H1ThhXsBKdu0J6zhlimLEzXBr0PcaSOSnLTFUFUz5jFgHMCxg1bVO9hFjlRqnKp3meOgRSyGW8L71zonRcmDyCT8GI6tkyZ4amLNZhCzJXEz808UPTJSP4uBr_9Yu9k6LkbdJ94k_w_f5BO_-pB6XTQmRGudzwrLDCqEwxiwAGHTwvPSsZj-ADcVeTLmOfrBlCEvBfKSuW3su4YEIh4olgJ6BEHbRh80o-9GADFvq_xEbwbt1Mb9K5tqZqr3oaTiCrSO-g4QxhMcJwFcHWUuTWv82Qc1Q3LoI8EMZgXMKWpv7VZxHnIuesyLbv7vpbeDg5Oz3RJ8fTr6_gEcJFRgflUrUDo25-Vb1GSNaVbwa9-wcgITXT |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3db9MwELdgCMQL3x-BAUFCgpe0je3YjngahWkDNk2CSRMvlu3EENEmVZsijb-eu3xUzSbxMKkPUXyu4tyd_bvo7neEvEm5E8xIQG7K-Ajwv4_S1PrI8czkgPBjx7E4-ehYHJzyz2fJ2VarryZp39liVM7mo7L41eRWLuZu3OeJjU-OpoxLRtNkvMj8-Dq5AT5LZR-od7EW7sIdk0-sxDjmUmCtToxlZDH2LaJUInMNu1DoPhucTw2N_-XNeuu0GmZSbh1N-3fJj35RbUbK79G6tiP39wLf45VWfY_c6QBruNeK3CfX8vIBudm2sDx_SL4dluGfol5WIaiomBcNrxPIY70EtqUIKx_m-Hke-YdDv2zrKFZ4e7o8X9TVLF8Uq3CFn02LEpMEavOInO5_-j49iLpGDZEVXNSRsHQCajaWuYkXE-czbrKUWogeU-EZowCSJplhwkBwMxE0E8ImKk-p8gl1gJAek52yKvOnJFTSKJX7WMo4A6QGZgTX1mcZtxnjRgbk_UBdetGScmikyR6OgMdq1LtGvWv8iYC865W7mdhEQUpcFv2Ayh_8f3OjWv7UnVo054lRmTQsSR03KlHUAUKCCNILTy1lAXmLpqNxs4BncqareYC1Iu2W3ksYp1wBpArI7kASnNwNh3vj090ms8LgDQGYSnlAXm-GcSYmzpV5tW5kGKK4NP6PDKOAuwHnq4A8ae15s-zeTQIiB5Y-eC_DEbDfhqa8s9dnV575itw6-bivvx4ef3lObgNSpZijF6tdslMv1_kLQIO1fdn4_T9oXF79 |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=In+vitro+antimicrobial+activity+of+ethanolic+fractions+of+Cryptolepis+sanguinolenta&rft.jtitle=Annals+of+clinical+microbiology+and+antimicrobials&rft.au=Mills-Robertson%2C+Felix+C&rft.au=Tay%2C+Samuel+C+K&rft.au=Duker-Eshun%2C+Goerge&rft.au=Walana%2C+Williams&rft.date=2012-06-18&rft.pub=BioMed+Central&rft.eissn=1476-0711&rft.volume=11&rft_id=info:doi/10.1186%2F1476-0711-11-16&rft.externalDocID=2789721001 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1476-0711&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1476-0711&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1476-0711&client=summon |